First graph, first sentence of release should read: CytoCore, Inc. (OTCBB:CYOE)(sted CytoCore, Inc. (OTCBB:CYTO)).
The corrected release reads:
CYTOCORE AND ZYCOM TO SIGN DISTRIBUTION AGREEMENT
CytoCore, Inc. (OTCBB:CYOE), the developer of cost effective products used for the detection of cancerous and precancerous conditions and privately held Zycom Touch, LLC., today announced that they have reached an agreement in principle for CytoCore to distribute OmniDROP™ on an exclusive basis to medical laboratories, hospitals, and HMO networks in the U.S. and non-exclusively internationally.
OmniDROP™ is the first bi-directional HIPAA-compliant peer-to-peer drop box communications software utility for Windows® and Apple® systems and is specifically designed to facilitate effective communications between physicians, medical laboratories, healthcare facilities, third party payors and patients. The program is offered on a subscription or fee-for-service basis depending upon the type of installation. OmniDROP is also designed to support the Ring Communicator™, a unique touch-enabled interface that organizes, manages and facilitates the complex communications inherent in many types of medical and dental procedures. CytoCore will offer OmniDROP as the HIPAA-compliant communications network for its Automated Imaging Proteomic Systems (AIPS™) Cytology Workstation as well as for communications between physicians, medical laboratories and healthcare facilities.
“We are pleased to select CytoCore as Zycom’s exclusive United States partner for the market launch of OmniDROP for laboratories, hospitals and HMOs in the United States. OmniDROP and the Ring Communicator will provide excellent communication features to the specimen screening, slide reporting and data management capabilities of CytoCore’s AIPS system,” stated John A. Ananian, President of Direct Response Medicine, LLC., the software developer and technology licensor to Zycom Touch, LLC. “We believe CytoCore’s medical systems industry experience will be integral to the adoption of our products within the healthcare chain of providers (physicians, laboratories, hospitals) and payors. Our combined products should dramatically lower provider expenses and increase operating efficiencies through reduction of paperwork and redundant operating procedures,” added Mr. Ananian.
“CytoCore’s AIPS workstation documentation management software in conjunction with Zycom’s OmniDROP and Ring Communicator will offer an effective communication tool for medical providers to meet the healthcare 'paper less' goals of the Obama Administration,” stated Robert McCullough, Jr., CytoCore’s CEO. “In addition, we expect that OmniDROP and the Ring Communicator will accelerate the adoption of CytoCore Solutions™ products by OB/GYNS and laboratories operating within healthcare networks. We anticipate initial roll out of the OmniDROP™ in the next 6 months with CytoCore earning a per transaction fee from Zycom,” stated McCullough. “These products will be either embedded in the AIPS workstation or implemented independently by healthcare providers. We are impressed by OmniDROP’s acceptance in the dental industry and believe these products will enhance the communication functions of CytoCore’s AIPS workstation within medical laboratories and affiliated hospital departments and referring physicians,” stated Richard Domanik, Chief Operating Officer of CytoCore, Inc.
OmniDROP combines a highly secure and reliable communications protocol with a user-friendly interface and the ability to send files and messages from any application. Workflow rules, message tracking, confirmation and alert functions ensure the traceability and accountability required by medical and other critical applications.
Privately held Zycom Touch, LLC. based in Temecula, California exclusively distributes OmniDROP™ and the Ring Communicator™ for healthcare and other industries.
About CytoCore Inc.
CytoCore develops cost-effective, highly accurate screening systems for early detection of gynecological and other cancers. Designed for easy deployment at a laboratory or at the point-of-care, the CytoCore suite of sample collection technologies assists in the detection of cervical, endometrial, and other cancers. The CytoCore Solutions™ System is being developed to provide medical practitioners with highly accurate, low-cost, cervical and uterine cancer screening systems that can be seamlessly integrated into existing medical models. More information is available at: www.CytoCoreInc.com.
Certain statements in this release are forward-looking. These statements are based on CytoCore's current expectations and involve many risks and uncertainties, such as the company's inability to obtain sufficient financing, the possibility that clinical trials will not substantiate CytoCore's expectations with respect to the CytoCore Solutions™ System, and other factors set forth in reports and documents filed by CytoCore with the Securities and Exchange Commission. Actual results may differ materially from CytoCore's current expectation depending upon a number of factors affecting the Company's business. These factors include, among others, risks and uncertainties detailed in the Company's periodic public filings with the Securities and Exchange Commission, including but not limited to the Company's Annual Report on Form 10-KSB for the year ended December 31, 2007. Except as expressly required by law, CytoCore undertakes no obligation to publicly update or revise any forward-looking statements contained herein.